Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy.
about
Mechanisms involved in the development of chemotherapy-induced neuropathyAstrocytes, but not microglia, are activated in oxaliplatin and bortezomib-induced peripheral neuropathy in the ratThe anti-diabetic drug metformin protects against chemotherapy-induced peripheral neuropathy in a mouse modelIdentifying Predictors of Taxane-Induced Peripheral Neuropathy Using Mass Spectrometry-Based Proteomics TechnologyTargeting neuroprotection as an alternative approach to preventing and treating neuropathic painAdenosine Monophosphate-activated Protein Kinase (AMPK) Activators For the Prevention, Treatment and Potential Reversal of Pathological Pain.Vascularization of the dorsal root ganglia and peripheral nerve of the mouse: implications for chemical-induced peripheral sensory neuropathiesToll-like receptor 4 signaling contributes to Paclitaxel-induced peripheral neuropathy.Repurposing Drugs in Oncology (ReDO)-mebendazole as an anti-cancer agentThe development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1.Antinociceptive Effect of Memantine and Morphine on Vincristine-induced Peripheral Neuropathy in Rats.Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing acute neurotoxicitySensitization of capsaicin and icilin responses in oxaliplatin treated adult rat DRG neurons.Spinal astrocytic activation contributes to mechanical allodynia in a rat chemotherapy-induced neuropathic pain model.Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in ratsTerminal arbor degeneration--a novel lesion produced by the antineoplastic agent paclitaxel.Protection against oxaliplatin-induced mechanical hyperalgesia and intraepidermal nerve fiber loss by minocycline.Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in miceMuscle pain in models of chemotherapy-induced and alcohol-induced peripheral neuropathyPaclitaxel induces acute pain via directly activating toll like receptor 4Retinoic acid reduces chemotherapy-induced neuropathy in an animal model and patients with lung cancer.Lysophosphatidic acid and its receptors LPA1 and LPA3 mediate paclitaxel-induced neuropathic pain in mice.Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy.Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel.Effects of mitochondrial poisons on the neuropathic pain produced by the chemotherapeutic agents, paclitaxel and oxaliplatin.Corneal Confocal Microscopy Detects Small Fibre Neuropathy in Patients with Upper Gastrointestinal Cancer and Nerve Regeneration in Chemotherapy Induced Peripheral NeuropathyNovel small molecule α9α10 nicotinic receptor antagonist prevents and reverses chemotherapy-evoked neuropathic pain in rats.The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA.Controlling murine and rat chronic pain through A3 adenosine receptor activationEfficient, large-scale synthesis and preclinical studies of MRS5698, a highly selective A3 adenosine receptor agonist that protects against chronic neuropathic pain.MAPK signaling downstream to TLR4 contributes to paclitaxel-induced peripheral neuropathy.CR4056, a new analgesic I2 ligand, is highly effective against bortezomib-induced painful neuropathy in rats.New Insights into Potential Prevention and Management Options for Chemotherapy-Induced Peripheral Neuropathy.Ghrelin prevents cisplatin-induced mechanical hyperalgesia and cachexia.Persistent chemoneuropathy in patients receiving the plant alkaloids paclitaxel and vincristineSubclinical peripheral neuropathy is a common finding in colorectal cancer patients prior to chemotherapyTargeting the overproduction of peroxynitrite for the prevention and reversal of paclitaxel-induced neuropathic painReview of the complications associated with treatment of oropharyngeal cancer: a guide for the dental practitioner.Chemotherapy-evoked neuropathic pain: Abnormal spontaneous discharge in A-fiber and C-fiber primary afferent neurons and its suppression by acetyl-L-carnitine.An overview of animal models of pain: disease models and outcome measures.
P2860
Q26824380-94560DA9-8EBC-42FC-B4A3-3A256BA15EEDQ28390312-C51EF8CC-C365-46C9-A7C4-3A74B4B3948CQ28539926-518FE306-F41F-4BDE-87F3-815881AC6CC5Q28551798-B79FFB6B-B1C4-490C-A6CC-DC54D678BC78Q28820780-677C3FE2-1F9F-49B0-AA5B-EE7ED282A235Q30383901-B67AA6B8-7811-4917-89A1-661561DED1F5Q33324545-C853F6F7-04E7-4F4B-BDA1-CFBB801AED6DQ33851825-C57C93CB-F7A5-4DE5-AA28-966FDEF38714Q33893928-E77DD129-30F0-4AA0-A9D7-372EB0718138Q33947251-82CE91ED-B46D-4574-8F3A-0B39073D8AFEQ34112816-315F5FEE-D35E-4EC4-8B43-966E3482DC71Q34339861-41BE03F0-E883-42CB-A40D-107FB8589850Q34412078-B0958347-9A19-4D4F-8693-C778310B5883Q34667811-B728A0C4-B923-4684-B151-39372E69ABFCQ34802605-D4A94C78-8F9B-438E-A90C-9B2D1EF9FB47Q34917256-C67F4FD5-BFD0-4D01-A3EF-AB0D90F927EDQ35000576-E1A48DC3-10CB-4EDB-95D8-6837F3ABB280Q35019148-2AD6CEE3-E2BE-48DA-A0F3-A9F5F2EBFE93Q35134836-0EF71B01-B03A-426E-82BF-E532617D43A6Q35187300-FCA228A3-7F40-44A0-823A-9BDAC2EB4563Q35210260-9EE935B0-CF43-410B-A4D2-CD82FD1D3A0CQ35438322-FDFFB88C-ECDF-409A-917B-DC5669020150Q35449249-988CF1AA-6094-4873-8397-C19589AAB2ABQ35740234-73F44E32-82EA-4155-833B-55C5439EFC77Q35784775-F4704BB0-0868-49E1-8B61-B3DCC98E7824Q35796623-376B342A-F692-497C-A83F-631AB262AD20Q35853738-79713DC0-C07F-4A26-89CD-9DB31800ACB3Q35898601-3D3BC974-B56B-4D24-9BE5-5E87DE85939FQ35913037-DDD9125E-96B0-480F-A0D2-F2FC83D1D7A7Q35930748-95925652-DD06-4713-BEF2-340FD4B55B36Q36053079-CC344486-3AC9-4843-85AB-F83993BF6CD3Q36084704-8963FFB9-F113-4FA4-987F-18EACBD92217Q36226275-BC99CDE9-AD99-49CB-84B6-3C47A48A51F6Q36415811-F0D08CE1-6B2C-4239-A1CA-644CF266199FQ36636831-FFB17249-6134-461F-A428-DC1EBD88FFE8Q36748075-EB3B92E5-6EF1-4F25-8A91-56B4BC558989Q37117256-CDD7C489-B458-42B6-8588-BD2E473A2E88Q37173814-C2BEA20B-AEFF-429E-946A-04DE54470017Q37209852-828ABE9C-3C02-4D82-8493-37B9C0659A5EQ37282107-E5884ADF-90B0-4593-A883-EC8592212060
P2860
Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Clinical and experimental find ...... induced peripheral neuropathy.
@ast
Clinical and experimental find ...... induced peripheral neuropathy.
@en
type
label
Clinical and experimental find ...... induced peripheral neuropathy.
@ast
Clinical and experimental find ...... induced peripheral neuropathy.
@en
prefLabel
Clinical and experimental find ...... induced peripheral neuropathy.
@ast
Clinical and experimental find ...... induced peripheral neuropathy.
@en
P2093
P1476
Clinical and experimental find ...... induced peripheral neuropathy.
@en
P2093
P304
P577
2006-03-01T00:00:00Z